Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies - Takeaways - MDSpire

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

  • By

  • Elvira Umyarova

  • John Sharp

  • Charles Pei

  • William Pellegrino

  • Qiuhong Zhao

  • Nathan Denlinger

  • Timothy Voorhees

  • Marcos De Lima

  • Narendranath Epperla

  • March 12, 2026

  • 0 min

Share

  • 1

    CAR T-cell therapy has improved outcomes for patients with relapsed or refractory hematologic malignancies, particularly B-cell lymphomas and B-ALL.

  • 2

    Cutaneous adverse events (AEs) occurred in 11% of patients post-CAR T-cell therapy, with maculopapular rash being the most common.

  • 3

    The majority of cutaneous AEs were early-onset, with 57% occurring within 30 days of CAR T-cell infusion.

  • 4

    No cutaneous AEs were observed in patients treated for multiple myeloma, contrasting with rates seen in registrational trials.

  • 5

    An increasing number of prior lines of therapy was associated with a lower risk of cutaneous AEs following CAR T-cell therapy.

Original Source(s)

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

  • by Elvira Umyarova, John Sharp, Charles Pei, William Pellegrino, Qiuhong Zhao, Nathan Denlinger, Timothy Voorhees, Marcos De Lima, Narendranath Epperla

  • March 12, 2026

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min